Biopsy Guidance Systems Market (2024 - 2030) Size, Share & Trends Analysis Report By Product (Stereotactic Guided Biopsy, Ultrasound Guided Biopsy, MRI Guided Biopsy), By Application, By End Use, By Region, And Segment Forecasts

Biopsy Guidance Systems Market Summary

The global biopsy guidance systems market size was estimated at USD 1.05 billion in 2023 and is projected to reach USD 1.58 billion by 2030, growing at a CAGR of 6.1% from 2024 to 2030. The key factors contributing to the growth of this market are an increase in the geriatric population, rising new incidences of cancer around the world, a growing inclination towards minimally invasive procedures, and advancements in imaging technology.

The increasing interest in using biopsy guidance systems for 3D imaging tests and minimally invasive treatments is expected to drive market growth in the forecast period.

The increasing prevalence of cancer is one of the key factors expected to boost the market during the forecast period. According to cancer facts and figures published by the American Cancer Society, as of January 1, 2022, 654,620 men and women in the U.S. had a history of lung cancer. The increasing cases of cancer are majorly the result of sedentary lifestyles, smoking, growing use of alcohol use, lack of exercise, poor nutrition, and obesity. This scenario is expected to drive demand for the biopsy guidance systems market during the forecast period.

The rising number of government initiatives and other non-government organizations' efforts in cancer awareness are expected to contribute to the market's growth. Breast cancer is the second most prevalent type of cancer worldwide, accounting for a significant proportion of cancer-related deaths among women. According to the World Health Organization (WHO), the five-year survival rate for breast cancer patients is 90% in high-income countries, 40% in South Africa, and 66% in India. In 2021, the WHO's Global Breast Cancer Initiative (GBCI) was established to reduce the breast cancer death rate by 2.5% annually, which is estimated to save 2.5 million lives over 20 years.

Product Insights

The stereotactic guided biopsy dominated the market and accounted for a share of 39.9% in 2023. It is beneficial as it is less obtrusive, gives fast recuperation time, and causes negligible scarring. Another benefit of using stereotactic guided biopsy is to assess small masses that are unclear on ultrasound, in contrast to traditional surgical biopsies. Furthermore, introducing automated core biopsy devices has increased the preference for this technique.

The ultrasound-guided biopsy section is expected to register the fastest CAGR during the forecast period.  It is the best real-time imaging tool for guiding percutaneous biopsies and fine-needle aspirations, and it is mainly used for abdominal and pelvic organs and masses. Some advantages of ultrasound-guided biopsy include smaller size, lower cost, and no exposure to ionizing radiation compared to CT-guided biopsies. Due to these advantages, ultrasound-guided breast biopsy is gaining popularity among patients, ultimately contributing to market growth.

End Use Insights

The healing centers segment dominated the industry and held the largest revenue share in 2023. It can be attributed to increased adoption of biopsy direction frameworks in clinics. Patients are choosing for minimally invasive surgeries to avoid certain conventional surgical intricacies and side effects. The rising number of people suffering from cancer is a key aspect driving growth for the healing centers segment. According to the Leukemia & Lymphoma Society (LLS), one individual is diagnosed with leukemia, lymphoma, or myeloma in the U.S. every three minutes.

The specialty clinics segment is anticipated to experience the fastest CAGR over the forecast period. The rise in acceptance of single-specialty healthcare has assisted this segment in providing potential to new and established enterprises. Budding awareness regarding the openness to diagnostics and screening procedures for chronic health conditions in such clinics generates greater demand for stereotactic-guided biopsies. Besides, the ability of specialty clinics to offer customized, personalized solutions for each type of cancer, combined with specialized infrastructural arrangements, is fueling the growth of this segment.

Application Insights

The brain biopsy section accounted for the largest market revenue share in 2023. Brain biopsy is considered the most reliable method to diagnose brain tumors that cannot be surgically removed. According to the NCBI 2023 report, brain biopsies are procedures with low rates of mortality and complex situations. Additionally, the expanding geriatric population is driving the number of brain biopsies across the world. Advancements in biopsy guidance systems, such as Magnetic Resonance Imaging (MRI) guided robotic systems for brain biopsies, are expected to contribute to the market growth.

The breast biopsy section is expected to experience the fastest CAGR during the forecast period. The rising occurrence of breast cancer cases is the key factor fueling this segment. Factors such as the prevalence of problems associated with menopause and increasing occurrences of hormonal imbalance are contributing to the rising number of women suffering from breast cancer.

Regional Insights

North America biopsy guidance system market dominated the market and accounted for revenue share of 45.4% in 2023. It can be attributed to the continuous expansions and growth of companies operating in cancer diagnostics, the demand for innovative strategies, and the rising number of people suffering from different types of cancer. Government organizations, non-profit healthcare establishments, pharmaceutical and biotech companies, and research institutes are investing significant resources in research and development, which is expected to drive market growth in the coming years.

U.S. Biopsy Guidance System Market Trends

The U.S. biopsy guidance system market is expected to experience a CAGR of 6.0% from 2024 to 2030. This is primarily due to the U.S. is witnessing unceasing growth in new cases associated with cancer, the increasing number of organizations and facilities providing cancer treatments, and technological advancements associated with biopsy guidance systems.

Europe Biopsy Guidance System Market Trends

The Europe biopsy guidance system market is identified as one of the significant regions for this industry. The growing acceptance of specialty care clinics in the region, the rapid rate of new cancer cases diagnosed every year, the presence of multiple prominent organizations providing cancer treatments, and increasing awareness regarding the significance of early treatments for cancer patients are expected to drive the growth for European market in approaching years.

The UK biopsy guidance system market held the largest revenue share in the regional industry. This can be attributed to various factors, such as the increase in the prevalence of numerous types of cancer, including blood cancer, enhancements in healthcare infrastructure, initiatives by the National Health Service, and the presence of key market participants in the country.

Asia Pacific Biopsy Guidance System Market Trends

The biopsy guided systems market in Asia Pacific is expected to experience the fastest CAGR during the forecast period. The growth attributed to an increased number of people diagnosed with various types of cancers. Similarly, improved healthcare infrastructure for cancer treatments and care, and the presence of international organizations in the market, are resulting in rising medical tourism and leading to market growth. A recent report put out by the National Cancer Registry Programme (NCRP) anticipated the number of cancer cases in India to surge from 13.9 lakhs in 2020 to 15.7 lakhs by 2025.

China biopsy guided systems market held a significant revenue share in 2023. This can be attributed to advancements in technologies such as magnetic resonance imaging (MRI), ultrasound-guided biopsy, CT imaging, robotic biopsies, government support, favorable reimbursements, enhanced infrastructure, and public health programs related to cancer screening and early detection.

Key Biopsy Guidance Systems Company Insights

Some of the key players operating in the biopsy guided systems market are Becton, Dickinson, and Company, Hologic, Inc., Devicor Medical Products, Inc., and others. Due to constantly growing demand and intense competition among market participants, the major companies are embracing strategies such as collaborations, innovation, enhanced investments in R&D, and expansions through mergers & acquisitions.

Recent Developments

• In January 2023, Becton, Dickinson, and Company, one of the major medical technology organizations, introduced a new robotic track system for the BD Kiestra microbiology laboratory solution. This innovative system enables automated specimen processing in laboratory settings.

Biopsy Guidance System Market Report Scope

Global Biopsy Guidance System Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global biopsy guidance system market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Stereotactic Guided Biopsy

  • Ultrasound Guided Biopsy

  • MRI Guided Biopsy

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Brain Biopsy

  • Breast Biopsy

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Specialty Clinics

  • Diagnostic Centers

  • Research and Academic Institutes

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait